In a study with seven ERA and two juvenile psoriatic arthritis cases, after one or two anti-TNF therapies failed (primary or secondary resistance to anti-TNF), secukinumab achieved inactive clinical disease [55]. This evidence concerns the gene TNF and psoriatic arthritis.